Medivir Promoted to NASDAQ OMX Stockholm Mid Cap List
Huddinge, Sweden - Medivir AB (OMX:MVIR), the emerging research-based
specialty pharmaceutical company focused on the development of
high-value treatments for infectious diseases, announces that NASDAQ OMX
Stockholm is promoting Medivir AB (MVIR B) from the Small Cap to the Mid
Cap List. The change is effective as of January 3, 2011.
Ron Long, CEO of Medivir commented, “Medivir has had a very successful
year with many important operational, as well as financial milestones
achieved during the year. The Medivir share price has performed strongly
during 2010 and our ambition of creating value for our shareholders will
continue. The move to the Mid Cap List is an important step for the
Company's future development.”
The NASDAQ Mid Cap List is for companies with a market cap between 150
million euro and 1 billion euro.
For more information about Medivir, please contact:
Medivir (www.medivir.se) Rein Piir, CFO & VP Investor Relations Office:
+46 8 546 831 23
Mobile:
+46 708 537 292
M:Communications
Medivir@mcomgroup.com (Medivir@mcomgroup.com)
Europe: Mary-Jane Elliott / Amber Bielecka / Nick Francis
+44(0)20 7920 2330
USA: Jason Marshall +1 212
897 5497
About Medivir
Medivir is a research-based specialty pharmaceutical company focused on
the development of high-value treatments for infectious diseases.
Medivir has world class expertise in polymerase and protease drug
targets and drug development. Medivir has a strong R&D portfolio and has
recently launched its first product Xerese™/Xerclear®. Medivir's key
pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical
development for Hepatitis C and is partnered with Tibotec
Pharmaceuticals.
Xerese™/Xerclear® is an innovative treatment for cold sores, which has
been approved in both the US and Europe. It is partnered with GSK to be
sold OTC in Europe and Russia and with Meda in North America. Medivir
has retained the Rx rights for Xerclear® in Sweden and Finland.
Medivir's key pipeline asset, TMC435, a protease inhibitor, is in phase
2b clinical development for Hepatitis C and is partnered with Tibotec
Pharmaceuticals.
For more information about Medivir, please visit the Company's website:
www.medivir.se.
Medivir Promoted to NASDAQ OMX Stockholm Mid Cap List
| Source: Medivir AB
Attachments
